Baseline patient and disease characteristics
| . | All patients . |
|---|---|
| N = 198 . | |
| Age, y | |
| Median (range) | 56.0 (18.9-81.5) |
| >60, n (%) | 75 (37.9) |
| Sex, n (%) | |
| Male | 109 (55.05) |
| Female | 89 (44.95) |
| AML etiology, n (%) | |
| De novo | 185 (93.4) |
| Secondary | 13 (6.6) |
| WBC, ×10⁹/L | |
| Median (range) | 25.7 (0.6-191.3) |
| >50, n (%) | 56 (28.3) |
| NA, n (%) | 2 (1.0) |
| FAB category, n (%) | |
| M0 | 4 (2.0) |
| M1 | 46 (23.2) |
| M2 | 43 (21.7) |
| M3 | 0 (0) |
| M4 | 51 (25.8) |
| M5 | 35 (17.7) |
| M6 | 4 (2.0) |
| M7 | 0 (0) |
| NA | 15 (7.6) |
| PB blasts, % | |
| Mean (SD) | 50.4 (32.9) |
| ELN classification, n (%) | |
| Favorable | 79 (39.9) |
| Intermediate | 119 (60.1) |
| CBF mutation, n (%) | 24 (12.1) |
| CEBPA mutation, n (%) | 20 (13.5) |
| NPM1 mutation, n (%) | 92 (53.8) |
| FLT3 mutation, n (%) | 58 (34.1) |
| Vγ9Vδ2 (% of LC) | |
| Mean (SD) | 2.5 (4.3) |
| 30-d mortality, n (%) | 3 (1.5) |
| 60-d mortality, n (%) | 11 (5.6) |
| CR after induction, n (%) | 161 (81.3) |
| HSCT, n (%) | 32 (16.3) |
| . | All patients . |
|---|---|
| N = 198 . | |
| Age, y | |
| Median (range) | 56.0 (18.9-81.5) |
| >60, n (%) | 75 (37.9) |
| Sex, n (%) | |
| Male | 109 (55.05) |
| Female | 89 (44.95) |
| AML etiology, n (%) | |
| De novo | 185 (93.4) |
| Secondary | 13 (6.6) |
| WBC, ×10⁹/L | |
| Median (range) | 25.7 (0.6-191.3) |
| >50, n (%) | 56 (28.3) |
| NA, n (%) | 2 (1.0) |
| FAB category, n (%) | |
| M0 | 4 (2.0) |
| M1 | 46 (23.2) |
| M2 | 43 (21.7) |
| M3 | 0 (0) |
| M4 | 51 (25.8) |
| M5 | 35 (17.7) |
| M6 | 4 (2.0) |
| M7 | 0 (0) |
| NA | 15 (7.6) |
| PB blasts, % | |
| Mean (SD) | 50.4 (32.9) |
| ELN classification, n (%) | |
| Favorable | 79 (39.9) |
| Intermediate | 119 (60.1) |
| CBF mutation, n (%) | 24 (12.1) |
| CEBPA mutation, n (%) | 20 (13.5) |
| NPM1 mutation, n (%) | 92 (53.8) |
| FLT3 mutation, n (%) | 58 (34.1) |
| Vγ9Vδ2 (% of LC) | |
| Mean (SD) | 2.5 (4.3) |
| 30-d mortality, n (%) | 3 (1.5) |
| 60-d mortality, n (%) | 11 (5.6) |
| CR after induction, n (%) | 161 (81.3) |
| HSCT, n (%) | 32 (16.3) |
CBF, core-bing factor; CEBPA, CCAAT enhancer binding protein alpha; FAB, French-American-British classification; FLT3, fms-like tyrosine kinase 3; LC, lymphocyte; NPM1, nucleophosmin 1; WBC, white blood cell; SD, standard deviation.